Search

Your search keyword '"Tolstrup M"' showing total 238 results

Search Constraints

Start Over You searched for: Author "Tolstrup M" Remove constraint Author: "Tolstrup M"
238 results on '"Tolstrup M"'

Search Results

1. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

4. The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon

5. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

6. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection

7. POS0546 REVACCINATION OF PATIENTS WITH SLE OR RA WITHOUT AN INITIAL COVID-19 VACCINE RESPONSE ELICITS SEROCONVERSION IN HALF OF THE PATIENTS

8. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

9. OP 1.9 – 00042 Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR trial

12. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

14. HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound

15. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

17. International AIDS Society global scientific strategy: towards an HIV cure 2016

19. Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits &ITEx Vivo&IT Lipopolysaccharide-Induced Inflammatory Responses

20. The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

21. The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon

22. Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs

23. REVACCINATION OF PATIENTS WITH SLE OR RA WITHOUT AN INITIAL COVID-19 VACCINE RESPONSE ELICITS SEROCONVERSION IN HALF OF THE PATIENTS.

24. Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption

26. 30-Day, 90-day and 1-year mortality after emergency colonic surgery

27. Complications after emergency laparotomy beyond the immediate postoperative period - a retrospective, observational cohort study of 1139 patients

28. 13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption

30. Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

32. Broad activation of latent HIV-1 in vivo

36. The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients

37. Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir

38. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

39. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission

40. Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System

41. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission

42. Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients

43. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

44. Peripheral blood CD4 + T cells and intestinal lamina propria mononuclear cells contribute to viremia following an analytical treatment interruption: a follow-up analysis of the panobinostat trial

45. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

46. Complications after emergency laparotomy beyond the immediate postoperative period - a retrospective, observational cohort study of 1139 patients.

49. Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation

50. Eliminating the latent HIV reservoir by reactivation strategies Advancing to clinical trials

Catalog

Books, media, physical & digital resources